02 — Linker Types
Overview
The linker is the pivotal element that determines where and when a payload is released. An ideal linker is:
- Plasma-stable: minimal premature cleavage during systemic circulation (days to weeks)
- Selectively cleavable: efficiently releases active payload inside the target cell
- Hydrophilic enough: does not increase ADC aggregation or accelerate clearance
- Compatible with conjugation chemistry: site-specific or stochastic conjugation must be chemically feasible
Linkers are broadly classified as cleavable or non-cleavable.
1. Cleavable Linkers
Release free payload upon a specific intracellular trigger (pH, enzyme, reducing environment).
1a. Acid-Labile Linkers (Hydrazone)
| Property | Detail |
|---|---|
| Cleavage trigger | Low pH (lysosomal, ~pH 4.5–5.5) |
| Chemical bond | C=N hydrazone or acylhydrazone |
| Approved example | Gemtuzumab ozogamicin (Mylotarg), inotuzumab ozogamicin (Besylomab) |
| Stability concern | Moderate plasma stability; some premature hydrolysis at physiological pH (7.4) |
| Payload release | Free calicheamicin released in endo/lysosomal compartment |
Limitation: Plasma hydrolysis rate is ~1–3%/day, contributing to systemic toxicity (hepatotoxicity with calicheamicin).
1b. Protease-Cleavable Linkers (Dipeptide)
The most widely used cleavable linker in modern ADCs.
| Property | Detail |
|---|---|
| Cleavage trigger | Cathepsin B (and other lysosomal cysteine proteases) |
| Chemical bond | Maleimide-Cys thioether + PEG spacer + dipeptide + PABC self-immolative spacer |
| Common dipeptides | Val-Cit (valine-citrulline); Val-Ala (valine-alanine) |
| Self-immolative spacer | Para-aminobenzyl carbamate (PABC) — undergoes 1,6-elimination to release free amine payload |
| Approved examples | Brentuximab vedotin (Val-Cit-PABC-MMAE); polatuzumab vedotin; enfortumab vedotin |
| Plasma stability | High; cathepsin B has minimal activity at neutral pH in plasma |
Val-Cit vs. Val-Ala: Val-Ala has faster cathepsin B cleavage kinetics and is slightly more hydrophilic; preferred for more polar linker-payload designs (e.g., some SG3199 ADCs use Val-Ala).
Self-immolation mechanism:
Cathepsin B cleaves: [mAb]–spacer–Val–Cit–↓–PABC–Payload
↓
PABC undergoes 1,6-elimination
↓
CO₂ + free H₂N-Payload
1c. Disulfide Linkers
| Property | Detail |
|---|---|
| Cleavage trigger | Intracellular glutathione (GSH; ~1–10 mM intracellular vs. ~2–20 µM plasma) |
| Chemical bond | S–S disulfide |
| Approved examples | None currently (used in some maytansinoid ADCs in development) |
| Stability issue | Thiol-disulfide exchange with plasma albumin or free thiols; requires steric hindering methyl groups |
| Optimization | gem-dimethyl substitution adjacent to disulfide (SPP vs. SPDB linkers) improves plasma stability |
DM4 conjugates (e.g., Elahere, mirvetuximab soravtansine) use a sulfo-SPDB disulfide linker — an improved, sulfonated disulfide with better hydrophilicity and stability than classic SPDB.
1d. Beta-Glucuronide Linkers
| Property | Detail |
|---|---|
| Cleavage trigger | Beta-glucuronidase (lysosomal enzyme) |
| Advantage | High hydrophilicity — enables conjugation to hydrophobic payloads without aggregation |
| Payload compatibility | Excellent for hydrophobic payloads (e.g., MMAE, SN-38 analogues) |
| Clinical status | Under clinical investigation; not yet approved as primary linker |
1e. Tetrapeptide Linkers (Enhertu-type)
| Property | Detail |
|---|---|
| Sequence | Gly-Gly-Phe-Gly (GGFG) |
| Cleavage trigger | Lysosomal cathepsins |
| ADC example | Trastuzumab deruxtecan (T-DXd / Enhertu) |
| Key feature | Ultra-hydrophilic, enables high DAR (≈8) without aggregation due to hydrophilic linker design |
| Payload released | DXd (free exatecan derivative) — membrane-permeable, enabling strong bystander effect |
2. Non-Cleavable Linkers (NCL)
Payload is not released by discrete linker cleavage. Instead, the entire antibody is degraded by lysosomal proteolysis, releasing an amino acid–linker–payload catabolite.
2a. Thioether (Succinimide-Thioether) via SMCC
| Property | Detail |
|---|---|
| Chemistry | Maleimide reacts with free thiol (lysine-reduced or engineered Cys) → succinimide-thioether |
| Crosslinker reagent | SMCC (succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) |
| Approved example | Ado-trastuzumab emtansine (T-DM1, Kadcyla) |
| Catabolite | Lys-SMCC-DM1 (charged, non-membrane-permeable) |
| Bystander effect | Minimal (catabolite cannot exit the cell efficiently) |
| Plasma stability | Excellent — no chemical cleavage trigger |
Limitation: Because catabolite cannot leave the killed cell, bystander effect is absent. NCL ADCs are best suited for targets with uniform, high antigen expression (e.g., HER2 in HER2-amplified cancers).
Retro-Michael risk: Maleimide-thiol adducts (not fully cyclized succinimide) can undergo retro-Michael addition in plasma, releasing maleimide-payload and transferring the payload to albumin Cys34. This reduces effective ADC exposure and requires careful ring-hydrolysis or site-specific conjugation strategies.
2b. MCC Linker (Cyclohexane-Containing)
- Similar to SMCC but with an alicyclic spacer for improved hydrophilicity.
- Used in some maytansinoid ADCs.
3. Conjugation Chemistry and DAR
The linker chemistry determines how the payload attaches to the antibody:
| Method | Site | Resulting DAR Distribution | DAR Range |
|---|---|---|---|
| Stochastic lysine conjugation | Lysine ε-NH₂ residues (~80 per IgG) | Heterogeneous (Gaussian distribution) | 0–8+ |
| Stochastic cysteine conjugation | Interchain cysteines (4 pairs in IgG1) | Heterogeneous but narrower | 0, 2, 4, 6, 8 |
| Site-specific (engineered Cys) | THIOMAB™ or SELENOMAB sites | Homogeneous DAR2 or DAR4 | 2 or 4 |
| Site-specific (unnatural amino acid) | Amber stop codon insertion | Homogeneous | 2 |
| Enzymatic (transglutaminase, glycan) | Specific Asn/Gln residues | Near-homogeneous | 2 |
Why DAR matters for bioanalysis: Stochastic conjugation produces a mixture of DAR0, DAR2, DAR4, DAR6, DAR8 species. Bioanalytical assays measuring “ADC” (conjugated Ab) must either average over this mixture or be designed to detect a specific DAR range. The average DAR is typically characterized by UV/Vis, HIC-HPLC, or intact mass spectrometry.
Linker Impact on PK
| Linker Type | Payload Release in Plasma | Effect on PK |
|---|---|---|
| Hydrazone (acid-labile) | Low-moderate leakage | Elevated free payload Cmax; hepatotoxicity risk |
| Val-Cit / Val-Ala | Minimal leakage | Clean separation of TAb vs. free payload exposure |
| Disulfide (hindered) | Low leakage with gem-dimethyl substitution | Albumin adduct formation possible |
| Non-cleavable thioether | Negligible leakage | Very stable ADC; TAb ≈ cAb over time |
| GGFG (T-DXd) | Minimal systemic leakage | High DAR stable; free DXd present at low levels |
Key Papers
- Doronina et al. (2003) Nat Biotechnol — Val-Cit-PABC-MMAE design and rationale
- Ducry & Stump (2010) Bioconjug Chem — comprehensive linker review
- Pillow et al. (2017) J Med Chem — site-specific conjugation comparison
- Ogitani et al. (2016) Clin Cancer Res — GGFG tetrapeptide linker in T-DXd